Under construction – not a live service
Sign in
Taking people in NorwayPhase 1

Tests patient's own immune cells loaded with clotting factor in hemophilia A

Tests the patient's own dendritic cells in adults with hemophilia A and inhibitor antibodies.

Key facts

Who runs it
Cell4Cure AB
Where
Oslo, NorwaySee the siteAlso in 1 other country, 1 site
Registry title
This is a first in human study, in patients with severe bleeding disorder (hemophilia A), who has developed inhibitory antibodies against coagulation factor VIII.The aim is to study the safety and efficacy of dendritic cells, originating from the patient itself. The dendritic cells has been loaded with coagulation factor VIII for an improved immunological tolerance. (TOLER8)
Status
Recruiting
Phase
Phase 1
People taking part
4 people, planned
Started
13 Oct 2022
Planned end
15 Apr 2025
Type of study
Interventional
Record updated
24 March 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with severe hemophilia A who have developed inhibitors (antibodies) against clotting factor VIII and whose earlier immune tolerance treatment did not work.

Age
18 to 64 years
Sex
Men only
Disease stage
Hemophilia A with inhibitory antibodies to clotting factor VIII, after failed immune tolerance induction
Earlier treatment
Immune tolerance induction was tried and failed
Biomarker or test result
Inhibitory antibodies against clotting factor VIII

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in Norway

Also in 1 other country, 1 site

  • Oslo University Hospital HFOslo, NorwayTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests patient's own immune cells loaded with clotting factor in hemophilia AGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2022-502030-12-01, who can take part
Record updated
24 March 2025